Philip Vickers

Philip Vickers, Ph.D., serves as chief executive officer of Faze Medicines and has over 30 years of experience as a researcher and leader in the pharmaceutical industry. He most recently served as president and CEO of Northern Biologics, Inc., a company developing first-in-class therapeutic antibodies targeting the tumor microenvironment. Preclinical and clinical programs at Northern Biologics were acquired by big pharma companies in 2020. Prior to his time at Northern Biologics, Dr. Vickers served as global head of research and development at Shire Pharmaceuticals, where he was a member of the executive leadership team. His breadth of experience includes leading roles at multiple global biotech and pharma companies, including Merck, Pfizer, Boehringer Ingelheim, and Resolvyx Pharmaceuticals, where he led teams in the development and approval of innovative small molecule and biologic therapeutics to treat diseases in a wide range of therapeutic areas. Dr. Vickers currently serves on the board of Revance Therapeutics, a company developing therapeutic agents based on novel delivery technologies for the neurotoxic protein botulinum toxin, and AVROBIO, a company developing lentiviral gene therapies to treat rare diseases. He earned his B.Sc. in applied biochemistry from the University of Salford in Manchester, England, and his Ph.D. in biochemistry from the University of Toronto in Ontario, Canada.